About this item:

19 Views | 3 Downloads

Author Notes:

Correspondence to: Raj Kishore, PhD, FAHA, Center for Translational Medicine, Temple University School of Medicine, MERB-953, 3500 N Broad Street, Philadelphia, PA 19140, Phone: 215-707-2523, Fax: 215-707-9890, raj.kishore@temple.edu, Michael Davis, PhD, FAHA, Department of Biomedical Engineering, Emory University School of Medicine, 1760 Haygood Drive, Suite W200, Atlanta, GA 30345, Phone: 404-727-9858, Fax: 404-727-9873, Michael.davis@bme.emory.edu.

Disclosures: None.

Subjects:

Research Funding:

This work was supported in part by funding from the National Institute of Health grants HL091983, HL126186 and HL134608 to RK and HL12438 to MED.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Cardiac & Cardiovascular Systems
  • Hematology
  • Peripheral Vascular Disease
  • Cardiovascular System & Cardiology
  • biology
  • exosomes
  • extracellular vesicles
  • lipids
  • stem cells
  • MESENCHYMAL STEM-CELLS
  • NANOPARTICLE TRACKING ANALYSIS
  • ACUTE MYOCARDIAL-INFARCTION
  • CARDIOSPHERE-DERIVED CELLS
  • PROGENITOR CELLS
  • ISCHEMIC CARDIOMYOPATHY
  • PERICARDIAL FLUID
  • MICROPARTICLE FORMATION
  • EXOSOMAL TRANSFER
  • ANGIOTENSIN-II

Extracellular Vesicles and the Application of System Biology and Computational Modeling in Cardiac Repair

Tools:

Journal Title:

Circulation Research

Volume:

Volume 123, Number 2

Publisher:

, Pages 188-204

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Recent literature suggests that extracellular vesicles (EVs), secreted from most cells and containing cellspecific cargo of proteins, lipids, and nucleic acids, are major driver of intracellular communication in normal physiology and pathological conditions. The recent evidence on stem/progenitor cell EVs as potential therapeutic modality mimicking their parental cell function is exciting because EVs could possibly be used as a surrogate for the stem cell-based therapy, and this regimen may overcome certain roadblocks identified with the use of stem/progenitor cell themselves. This review provides a comprehensive update on our understanding on the role of EVs in cardiac repair and emphasizes the applications of stem/progenitor cell-derived EVs as therapeutics and discusses the current challenges associated with the EV therapy.

Copyright information:

© 2018 American Heart Association, Inc.

Export to EndNote